Infliximab drug survival in chronic plaque psoriasis: follow-up of the product familiarisation program

Australas J Dermatol. 2020 Nov;61(4):e472-e474. doi: 10.1111/ajd.13293. Epub 2020 Apr 20.

Authors

William Berry¹, Benjamin Daniel¹, Rebecca Nguyen², Chris Baker^{1

2

3}, Peter Foley^{1

2

3}

Affiliations

¹ St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
² Skin Health Institute, Carlton, Victoria, Australia.
³ Department of Medicine (Dermatology), The University of Melbourne, Parkville, Victoria, Australia.

PMID: 32314344
DOI: 10.1111/ajd.13293

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use*
Female
Follow-Up Studies
Humans
Infliximab / adverse effects
Infliximab / therapeutic use*
Lost to Follow-Up
Male
Middle Aged
Psoriasis / drug therapy*
Severity of Illness Index

Substances

Dermatologic Agents
Infliximab